Covered Companies: Akari Therapeutics
Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases.
NASDAQ: AKTX
About
Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recominant inhibitor of complement C5 and leukotriene B4 (LTB4) activity. Akari’s pipeline includes Phase 3 clinical trials investigating nomacopan for both pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Their pipeline also includes a pre-clinical program developing long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA).
Join Us
Sign up for email alerts to stay up-to-date on the latest Virtual Investor events
By submitting this form, you are consenting to receive marketing emails from: Virtual Investor. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact